CoChat

Structural aspects of chemical modifications in the MHC-restricted immunopeptidome; Implications for immune recognition

Sandalova, Tatyana, Sala, Benedetta Maria, Achour, Adnane · 2022 · Frontiers in Chemistry
Cited by 21

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Significant advances in mass-spectroscopy (MS) have made it possible to investigate the cellular immunopeptidome, a large collection of MHC-associated epitopes presented on the surface of healthy, stressed and infected cells. These approaches have hitherto allowed the unambiguous identification of large cohorts of epitope sequences that are restricted to specific MHC class I and II molecules, enhancing our understanding of the quantities, qualities and origins of these peptide populations. Most importantly these analyses provide essential information about the immunopeptidome in responses to pathogens, autoimmunity and cancer, and will hopefully allow for future tailored individual therapies. Protein post-translational modifications (PTM) play a key role in cellular functions, and are essential for both maintaining cellular homeostasis and increasing the diversity of the proteome. A significant proportion of proteins is post-translationally modified, and thus a deeper understanding of the importance of PTM epitopes in immunopeptidomes is essential for a thorough and stringent understanding of these peptide populations. The aim of the present review is to provide a structural insight into the impact of PTM peptides on stability of MHC/peptide complexes, and how these may alter/modulate immune responses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fchem.2022.861609

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 153

  1. Achour, 2002, A structural basis for LCMV immune evasion: Subversion of H-2D(b) and H-2K(b) presentation of gp33 revealed by comparative crystal structure.Analyses, Immunity, 17, 757, 10.1016/s1074-7613(02)00478-8 · DOI
  2. Alpízar, 2017, A molecular basis for the presentation of phosphorylated peptides by HLA-B antigens, Mol. Cell. Proteomics, 16, 181, 10.1074/mcp.m116.063800 · DOI · Paper page
  3. Andersen, 1999, Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL, J. Immunol., 163, 3812, 10.4049/jimmunol.163.7.3812 · DOI · Paper page
  4. Ayyoub, 1999, A structure-based approach to designing non-natural peptides that can activate anti-melanoma cytotoxic T cells, J. Biol. Chem., 274, 10227, 10.1074/jbc.274.15.10227 · DOI
  5. Bagdonaite, 2018, Global aspects of viral glycosylation, Glycobiology, 28, 443, 10.1093/glycob/cwy021 · DOI · Paper page
  6. Baker, 2000, Conversion of a T cell antagonist into an agonist by repairing a defect in the TCR/peptide/MHC interface: Implications for TCR signaling, Immunity, 13, 475, 10.1016/s1074-7613(00)00047-9 · doi:10.1016/s1074-7613(00)00047-9
  7. Bassani-Sternberg, 2015, Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation, Mol. Cell. Proteomics, 14, 658, 10.1074/mcp.m114.042812 · DOI · Paper page
  8. Beltrami, 2008, Citrullination-dependent differential presentation of a self-peptide by HLA-B27 subtypes, J. Biol. Chem., 283, 27189, 10.1074/jbc.m802818200 · DOI
  9. Bennun, 2013, Integration of the transcriptome and glycome for identification of glycan cell signatures, PLoS Comput. Biol., 9, e1002813, 10.1371/journal.pcbi.1002813 · DOI · Paper page
  10. Bergseng, 2015, Different binding motifs of the celiac disease-associated HLA molecules DQ2.5, DQ2.2, and DQ7.5 revealed by relative quantitative proteomics of endogenous peptide repertoires, Immunogenetics, 67, 73, 10.1007/s00251-014-0819-9 · DOI · Paper page
  11. Blees, 2017, Structure of the human MHC-I peptide-loading complex, Nature, 551, 525, 10.1038/nature24627 · DOI · Paper page
  12. Blum, 2013, Pathways of antigen processing, Annu. Rev. Immunol., 31, 443, 10.1146/annurev-immunol-032712-095910 · DOI · Paper page
  13. Bourdetsky, 2014, The nature and extent of contributions by defective ribosome products to the HLA peptidome, Proc. Natl. Acad. Sci. U. S. A., 111, E1591, 10.1073/pnas.1321902111 · DOI
  14. Brewerton, 1973, Ankylosing spondylitis and HL-A 27, Lancet, 1, 904, 10.1016/s0140-6736(73)91360-3 · DOI · Paper page
  15. Bruning, 2018, Impairment of angiogenesis by fatty acid synthase inhibition involves mTOR malonylation, Cell. Metab., 28, 866, 10.1016/j.cmet.2018.07.019 · DOI · Paper page
  16. Cable, 2021, Frontiers in cancer immunotherapy-a symposium report, Ann. N. Y. Acad. Sci., 1489, 30, 10.1111/nyas.14526 · DOI
  17. Campbell, 2018, Metabolic signaling to the nucleus in cancer, Mol. Cell., 71, 398, 10.1016/j.molcel.2018.07.015 · DOI · Paper page
  18. Caron, 2015, Analysis of major histocompatibility complex (MHC) immunopeptidomes using mass spectrometry, Mol. Cell. Proteomics, 14, 3105, 10.1074/mcp.o115.052431 · DOI · Paper page
  19. Celie, 2009, UV-induced ligand exchange in MHC class I protein crystals, J. Am. Chem. Soc., 131, 12298, 10.1021/ja9037559 · DOI
  20. Chambers, 2007, Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination, Cancer Res., 67, 8450, 10.1158/0008-5472.can-07-1092 · DOI
  21. Chang, 2016, Human oncogenic herpesvirus and post-translational modifications - phosphorylation and SUMOylation, Front. Microbiol., 7, 962, 10.3389/fmicb.2016.00962 · doi:10.3389/fmicb.2016.00962
  22. Chen, 2017, Role of HLA-B27 in the pathogenesis of ankylosing spondylitis, Mol. Med. Rep., 15, 1943, 10.3892/mmr.2017.6248 · DOI · Paper page
  23. Chen, 2005, Structural and kinetic basis for heightened immunogenicity of T cell vaccines, J. Exp. Med., 201, 1243, 10.1084/jem.20042323 · DOI · Paper page
  24. Chen, 2018, Post-translational modification-based regulation of HIV replication, Front. Microbiol., 9, 2131, 10.3389/fmicb.2018.02131 · DOI
  25. Chessman, 2008, Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity, Immunity, 28, 822, 10.1016/j.immuni.2008.04.020 · DOI · Paper page
  26. Compañón, 2019, Structure-based design of potent tumor-associated antigens: Modulation of peptide presentation by single-atom O/S or O/Se substitutions at the glycosidic linkage, J. Am. Chem. Soc., 141, 4063, 10.1021/jacs.8b13503 · DOI
  27. Cook, 2018, Citrullinated α-enolase is an effective target for anti-cancer immunity, Oncoimmunology, 7, e1390642, 10.1080/2162402x.2017.1390642 · DOI · Paper page
  28. Depontieu, 2009, Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy, Proc. Natl. Acad. Sci. U. S. A., 106, 12073, 10.1073/pnas.0903852106 · DOI · Paper page
  29. Dersh, 2021, A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion, Nat. Rev. Immunol., 21, 116, 10.1038/s41577-020-0390-6 · DOI · Paper page
  30. Ding, 1999, Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical, Immunity, 11, 45, 10.1016/s1074-7613(00)80080-1 · DOI · Paper page
  31. Diskin, 2021, Modification of proteins by metabolites in immunity, Immunity, 54, 19, 10.1016/j.immuni.2020.09.014 · DOI · Paper page
  32. Dudler, 1995, Carbohydrate-dependent, HLA class II-restricted, human T cell response to the bee venom allergen phospholipase A2 in allergic patients, Eur. J. Immunol., 25, 538, 10.1002/eji.1830250235 · DOI · Paper page
  33. Duraj, 2021, Metabolic therapy and bioenergetic analysis: The missing piece of the puzzle, Mol. Metab., 54, 101389, 10.1016/j.molmet.2021.101389 · DOI
  34. Duru, 2020, Tuning antiviral CD8 T-cell response via proline-altered peptide ligand vaccination, PLoS Pathog., 16, e1008244, 10.1371/journal.ppat.1008244 · DOI · Paper page
  35. Ene, 2020, Posttranslational modifications pattern in clear cell renal cell carcinoma, Metabolites, 11, 10, 10.3390/metabo11010010 · DOI
  36. Faridi, 2018, A subset of HLA-I peptides are not genomically templated: Evidence for cis- and trans-spliced peptide ligands, Sci. Immunol., 3, eaar3947, 10.1126/sciimmunol.aar3947 · DOI · Paper page
  37. Fremont, 1992, Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb, Science, 257, 919, 10.1126/science.1323877 · DOI · Paper page
  38. Fugmann, 2017, The MHC class II immunopeptidome of lymph nodes in health and in chemically induced colitis, J. I., 198, 1357, 10.4049/jimmunol.1601157 · DOI
  39. Gerstner, 2016, Functional and structural characterization of a novel HLA-drb1*04:01-restricted α-enolase T cell epitope in rheumatoid arthritis, Front. Immunol., 7, 494, 10.3389/fimmu.2016.00494 · DOI · Paper page
  40. Ghanem, 2021, The pentose phosphate pathway in cancer: Regulation and therapeutic opportunities, Chemotherapy, 66, 179, 10.1159/000519784 · DOI
  41. Glithero, 1999, Crystal structures of two H-2Db/glycopeptide complexes suggest a molecular basis for CTL cross-reactivity, Immunity, 10, 63, 10.1016/s1074-7613(00)80007-2 · DOI
  42. Gómez-Nuñez, 2008, Non-natural and photo-reactive amino acids as biochemical probes of immune function, PLoS One, 3, e3938, 10.1371/journal.pone.0003938 · DOI
  43. Granados, 2015, The nature of self for T cells-a systems-level perspective, Curr. Opin. Immunol., 34, 1, 10.1016/j.coi.2014.10.012 · DOI
  44. Guichard, 1996, Partially modified retro-inverso pseudopeptides as non-natural ligands for the human class I histocompatibility molecule HLA-A2, J. Med. Chem., 39, 2030, 10.1021/jm9509511 · DOI · Paper page
  45. Hafstrand, 2017, Crystal structures of H-2Db in complex with the LCMV-derived peptides GP92 and GP392 explain pleiotropic effects of glycosylation on antigen presentation and immunogenicity, PLoS One, 12, e0189584, 10.1371/journal.pone.0189584 · DOI
  46. Hafstrand, 2016, The MHC class I cancer-associated neoepitope Trh4 linked with impaired peptide processing induces a unique noncanonical TCR conformer, J. I., 196, 2327, 10.4049/jimmunol.1502249 · doi:10.4049/jimmunol.1502249
  47. Hafstrand, 2018, The immunogenicity of a proline-substituted altered peptide ligand toward the cancer-associated TEIPP neoepitope Trh4 is unrelated to complex stability, J. I., 200, 2860, 10.4049/jimmunol.1700228 · DOI
  48. Hanada, 2004, Immune recognition of a human renal cancer antigen through post-translational protein splicing, Nature, 427, 252, 10.1038/nature02240 · DOI · Paper page
  49. Hardy, 2008, Conversion of tyrosine to the inflammation-associated analog 3'-nitrotyrosine at either TCR- or MHC-contact positions can profoundly affect recognition of the MHC class I-restricted epitope of lymphocytic choriomeningitis virus glycoprotein 33 by CD8 T cells, J. Immunol., 180, 5956, 10.4049/jimmunol.180.9.5956 · DOI · Paper page
  50. Harriff, 2017, HLA-E presents glycopeptides from the Mycobacterium tuberculosis protein MPT32 to human CD8+ T cells, Sci. Rep., 7, 4622, 10.1038/s41598-017-04894-0 · DOI
  51. Hastie, 2016, Crystal structure of the prefusion surface glycoprotein of the prototypic arenavirus LCMV, Nat. Struct. Mol. Biol., 23, 513, 10.1038/nsmb.3210 · DOI
  52. Herzog, 2005, Activated antigen-presenting cells select and present chemically modified peptides recognized by unique CD4 T cells, Proc. Natl. Acad. Sci. U. S. A., 102, 7928, 10.1073/pnas.0502255102 · DOI · Paper page
  53. Hoppes, 2014, Altered peptide ligands revisited: Vaccine design through chemically modified HLA-A2-restricted T cell epitopes, J. I., 193, 4803, 10.4049/jimmunol.1400800 · DOI · Paper page
  54. Hudrisier, 2001, Molecular and functional dissection of the H-2Db-restricted subdominant cytotoxic T-cell response to lymphocytic choriomeningitis virus, J. Virol., 75, 2468, 10.1128/jvi.75.5.2468-2471.2001 · doi:10.1128/jvi.75.5.2468-2471.2001
  55. Hudrisier, 1999, Genetically encoded and post-translationally modified forms of a major histocompatibility complex class I-restricted antigen bearing a glycosylation motif are independently processed and co-presented to cytotoxic T lymphocytes, J. Biol. Chem., 274, 36274, 10.1074/jbc.274.51.36274 · DOI
  56. Hülsmeyer, 2004, Dual, HLA-B27 subtype-dependent conformation of a self-peptide, J. Exp. Med., 199, 271, 10.1084/jem.20031690 · DOI
  57. Illing, 2018, HLA-B57 micropolymorphism defines the sequence and conformational breadth of the immunopeptidome, Nat. Commun., 9, 4693, 10.1038/s41467-018-07109-w · DOI
  58. Irvine, 2020, Understanding the role of antibody glycosylation through the lens of severe viral and bacterial diseases, Glycobiology, 30, 241, 10.1093/glycob/cwaa018 · DOI
  59. Istrail, 2004, Comparative immunopeptidomics of humans and their pathogens, Proc. Natl. Acad. Sci. U. S. A., 101, 13268, 10.1073/pnas.0404740101 · DOI · Paper page
  60. James, 2010, HLA-DR1001 presents "altered-self" peptides derived from joint-associated proteins by accepting citrulline in three of its binding pockets, Arthritis Rheum., 62, 2909, 10.1002/art.27594 · DOI
  61. Jarrold, 2019, PRMTs and arginine methylation: Cancer's best-kept secret?, Trends Mol. Med., 25, 993, 10.1016/j.molmed.2019.05.007 · DOI · Paper page
  62. Jennewein, 2017, The immunoregulatory roles of antibody glycosylation, Trends Immunol., 38, 358, 10.1016/j.it.2017.02.004 · DOI · Paper page
  63. Jiang, 2021, Wilms tumor gent 1 (WT1)-specific adoptive immunotherapy in hematologic diseases, Int. Immunopharmacol., 94, 107504, 10.1016/j.intimp.2021.107504 · DOI
  64. Jones, 2006, Synthesis and biological evaluation of two chemically modified peptide epitopes for the class I MHC protein HLA-B*2705, Org. Biomol. Chem., 4, 3769, 10.1039/b611170j · doi:10.1039/b611170j
  65. Kanaseki, 2006, ERAAP synergizes with MHC class I molecules to make the final cut in the antigenic peptide precursors in the endoplasmic reticulum, Immunity, 25, 795, 10.1016/j.immuni.2006.09.012 · DOI
  66. Kastrup, 2001, MHC-restricted T cell responses against posttranslationally modified peptide antigens, Adv. Immunol., 78, 267, 10.1016/s0065-2776(01)78006-6 · DOI
  67. Khan, 2013, Polymorphism of HLA-B27: 105 subtypes currently known, Curr. Rheumatol. Rep., 15, 362, 10.1007/s11926-013-0362-y · DOI
  68. Kiessling, 2016, TAP-ing into TIEPPs for cancer immunotherapy, J. Clin. Invest., 126, 480, 10.1172/jci86119 · doi:10.1172/jci86119
  69. Klein, 1986, Seeds of time: Fifty years ago peter A. Gorer discovered the H-2 complex, Immunogenetics, 24, 331, 10.1007/bf00377947 · doi:10.1007/bf00377947
  70. Kloetzel, 2001, Antigen processing by the proteasome, Nat. Rev. Mol. Cell. Biol., 2, 179, 10.1038/35056572 · DOI · Paper page
  71. Kloetzel, 2022, Neo-splicetopes in tumor therapy: A lost case?, Front. Immunol., 13, 849863, 10.3389/fimmu.2022.849863 · DOI
  72. Knierman, 2020, The human leukocyte antigen class II immunopeptidome of the SARS-CoV-2 spike glycoprotein, Cell. Rep., 33, 108454, 10.1016/j.celrep.2020.108454 · DOI · Paper page
  73. Krebs, 1998, Binding of rationally designed non-natural peptides to the human leukocyte antigen HLA-B*2705, J. Pept. Sci., 4, 378, 10.1002/(sici)1099-1387(199809)4:6<378::aid-psc157>3.0.co;2-b · doi:10.1002/(sici)1099-1387(199809)4:6<378::aid-psc157>3.0.co;2-b
  74. Kumar, 2020, Role of host-mediated post-translational modifications (PTMs) in RNA virus pathogenesis, Int. J. Mol. Sci., 22, 323, 10.3390/ijms22010323 · DOI · Paper page
  75. Lampen, 2018, Breadth and dynamics of HLA-A2– and HLA-B7–restricted CD8+ T cell responses against nonstructural viral proteins in acute human tick-borne encephalitis virus infection, Immunohorizons, 2, 172, 10.4049/immunohorizons.1800029 · DOI
  76. Lande, 2021, Complementary effects of carbamylated and citrullinated LL37 in autoimmunity and inflammation in systemic lupus erythematosus, Int. J. Mol. Sci., 22, 1650, 10.3390/ijms22041650 · DOI
  77. Lawrence, 2013, Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, 499, 214, 10.1038/nature12213 · DOI · Paper page
  78. Leeming, 2011, Post-translational modifications of the extracellular matrix are key events in cancer progression: Opportunities for biochemical marker development, Biomarkers, 16, 193, 10.3109/1354750x.2011.557440 · DOI
  79. Liepe, 2016, A large fraction of HLA class I ligands are proteasome-generated spliced peptides, Science, 354, 354, 10.1126/science.aaf4384 · DOI · Paper page
  80. Lim, 2021, The shared susceptibility epitope of HLA-DR4 binds citrullinated self-antigens and the TCR, Sci. Immunol., 6, eabe0896, 10.1126/sciimmunol.abe0896 · DOI
  81. Lindqvist, 2009, Structural basis for substrate recognition and specificity in aklavinone-11-hydroxylase from rhodomycin biosynthesis, J. Mol. Biol., 393, 966, 10.1016/j.jmb.2009.09.003 · doi:10.1016/j.jmb.2009.09.003
  82. Linnemann, 2015, High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma, Nat. Med., 21, 81, 10.1038/nm.3773 · DOI · Paper page
  83. Liu, 2021, IgG N-glycans, Adv. Clin. Chem., 105, 1, 10.1016/bs.acc.2021.02.001 · DOI
  84. Liu, 2019, A cell-penetrating peptide-assisted nanovaccine promotes antigen cross-presentation and anti-tumor immune response, Biomater. Sci., 7, 5516, 10.1039/c9bm01183h · DOI
  85. Madhurantakam, 2012, Inflammation-associated nitrotyrosination affects TCR recognition through reduced stability and alteration of the molecular surface of the MHC complex, PLoS One, 7, e32805, 10.1371/journal.pone.0032805 · DOI
  86. Malaker, Identification and characterization of complex glycosylated peptides presented by the MHC class II processing pathway in melanoma, J. Proteome Res., 16, 228, 10.1021/acs.jproteome.6b00496 · DOI · Paper page
  87. Malaker, Identification of glycopeptides as posttranslationally modified neoantigens in leukemia, Cancer Immunol. Res., 5, 376, 10.1158/2326-6066.cir-16-0280 · DOI · Paper page
  88. Mann, 2003, Proteomic analysis of post-translational modifications, Nat. Biotechnol., 21, 255, 10.1038/nbt0303-255 · DOI · Paper page
  89. Marijt, TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class Ilow cancers, Mol. Immunol., 113, 43, 10.1016/j.molimm.2018.03.029 · DOI
  90. Marijt, TEIPP peptides: Exploration of unTAPped cancer antigens, Oncoimmunology, 8, 1599639, 10.1080/2162402x.2019.1599639 · DOI
  91. Marino, 2015, Extended O-GlcNAc on HLA class-I-bound peptides, J. Am. Chem. Soc., 137, 10922, 10.1021/jacs.5b06586 · DOI · Paper page
  92. Mei, 2020, Immunopeptidomic analysis reveals that deamidated HLA-bound peptides arise predominantly from deglycosylated precursors, Mol. Cell. Proteomics, 19, 1236, 10.1074/mcp.ra119.001846 · DOI · Paper page
  93. Mereiter, 2019, Glycosylation in the era of cancer-targeted therapy: Where are we heading?, Cancer Cell., 36, 6, 10.1016/j.ccell.2019.06.006 · DOI · Paper page
  94. Michaëlsson, 1994, T cell recognition of carbohydrates on type II collagen, J. Exp. Med., 180, 745, 10.1084/jem.180.2.745 · DOI · Paper page
  95. Mishto, 2019, An in silico—In vitro pipeline identifying an HLA-A*02:01+ KRAS G12V+ spliced epitope candidate for a broad tumor-immune response in cancer patients, Front. Immunol., 10, 2572, 10.3389/fimmu.2019.02572 · DOI · Paper page
  96. Mizukoshi, 2011, Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma, Hepatology, 53, 1206, 10.1002/hep.24149 · DOI · Paper page
  97. Mohammed, 2017, The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status, Oncotarget, 8, 54160, 10.18632/oncotarget.16952 · DOI · Paper page
  98. Mommen, 2014, Expanding the detectable HLA peptide repertoire using electron-transfer/higher-energy collision dissociation (EThcD), Proc. Natl. Acad. Sci. U. S. A., 111, 4507, 10.1073/pnas.1321458111 · DOI · Paper page
  99. Mommen, 2016, Sampling from the proteome to the human leukocyte antigen-DR (HLA-DR) ligandome proceeds via high specificity, Mol. Cell. Proteomics, 15, 1412, 10.1074/mcp.m115.055780 · DOI
  100. Mondal, 2021, Chemical biology of protein citrullination by the protein A arginine deiminases, Curr. Opin. Chem. Biol., 63, 19, 10.1016/j.cbpa.2021.01.010 · DOI
  101. Morita, 2016, Lipopeptides: A novel antigen repertoire presented by major histocompatibility complex class I molecules, Immunology, 149, 139, 10.1111/imm.12646 · DOI
  102. Newton, 2018, Protein kinase C: Perfectly balanced, Crit. Rev. Biochem. Mol. Biol., 53, 208, 10.1080/10409238.2018.1442408 · DOI · Paper page
  103. Nguyen, 2021, Can glycosylation mask the detection of MHC expressing p53 peptides by T cell receptors?, Biomolecules, 11, 1056, 10.3390/biom11071056 · DOI
  104. Nuriel, 2011, Protein nitrotryptophan: Formation, significance and identification, J. Proteomics, 74, 2300, 10.1016/j.jprot.2011.05.032 · DOI · Paper page
  105. Olsen, 2006, Global, in vivo, and site-specific phosphorylation dynamics in signaling networks, Cell., 127, 635, 10.1016/j.cell.2006.09.026 · DOI · Paper page
  106. Olvera, 2020, Does antigen glycosylation impact the HIV-specific T cell immunity?, Front. Immunol., 11, 573928, 10.3389/fimmu.2020.573928 · DOI
  107. Parker, 2021, Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells, Cell. Rep., 35, 109179, 10.1016/j.celrep.2021.109179 · DOI · Paper page
  108. Pearson, 2016, MHC class I-associated peptides derive from selective regions of the human genome, J. Clin. Invest., 126, 4690, 10.1172/jci88590 · DOI · Paper page
  109. Peixoto, 2019, Protein glycosylation and tumor microenvironment alterations driving cancer hallmarks, Front. Oncol., 9, 380, 10.3389/fonc.2019.00380 · DOI · Paper page
  110. Petersen, Post-translationally modified T cell epitopes: Immune recognition and immunotherapy, J. Mol. Med., 87, 1045, 10.1007/s00109-009-0526-4 · DOI
  111. Petersen, Phosphorylated self-peptides alter human leukocyte antigen class I-restricted antigen presentation and generate tumor-specific epitopes, Proc. Natl. Acad. Sci. U. S. A., 106, 2776, 10.1073/pnas.0812901106 · DOI · Paper page
  112. Pieper, 2018, Memory T cells specific to citrullinated α-enolase are enriched in the rheumatic joint, J. Autoimmun., 92, 47, 10.1016/j.jaut.2018.04.004 · DOI
  113. Powell, 1992, Peptide stability in drug development: A comparison of peptide reactivity in different biological media, J. Pharm. Sci., 81, 731, 10.1002/jps.2600810802 · DOI
  114. Proulx, 2020, Post-translational modifications inducing proteasomal degradation to counter HIV-1 infection, Virus Res., 289, 198142, 10.1016/j.virusres.2020.198142 · DOI
  115. Prus, 2019, Analysis and interpretation of protein post-translational modification site stoichiometry, Trends biochem. Sci., 44, 943, 10.1016/j.tibs.2019.06.003 · DOI · Paper page
  116. Rane, 2019, P21 activated kinase signaling in cancer, Semin. Cancer Biol., 54, 40, 10.1016/j.semcancer.2018.01.006 · DOI · Paper page
  117. Revathidevi, 2019, Akt in cancer: Mediator and more, Semin. Cancer Biol., 59, 80, 10.1016/j.semcancer.2019.06.002 · DOI · Paper page
  118. Richman, 1979, Cancer immunotherapy, Can. Med. Assoc. J., 120, 322
  119. Rosado, 2021, ADP-ribosylation in evasion, promotion and exacerbation of immune responses, Immunology, 164, 15, 10.1111/imm.13332 · DOI
  120. Rosendahl Huber, 2016, Chemical modification of influenza CD8+ T-cell epitopes enhances their immunogenicity regardless of immunodominance, PLoS One, 11, e0156462, 10.1371/journal.pone.0156462 · DOI
  121. Santos, 2017, Protein posttranslational modifications: Roles in aging and age-related disease, Oxid. Med. Cell. Longev., 2017, 5716409, 10.1155/2017/5716409 · DOI · Paper page
  122. Schuster, 2018, A tissue-based draft map of the murine MHC class I immunopeptidome, Sci. Data, 5, 180157, 10.1038/sdata.2018.157 · DOI
  123. Seo, 2004, Post-translational modifications and their biological functions: Proteomic analysis and systematic approaches, BMB Rep., 37, 35, 10.5483/bmbrep.2004.37.1.035 · DOI · Paper page
  124. Shao, 2018, The SysteMHC atlas project, Nucleic Acids Res., 46, D1237, 10.1093/nar/gkx664 · DOI · Paper page
  125. Sidney, 2018, Low HLA binding of diabetes-associated CD8+ T-cell epitopes is increased by post translational modifications, BMC Immunol., 19, 12, 10.1186/s12865-018-0250-3 · DOI · Paper page
  126. Singh, 2017, Phosphorylation: Implications in cancer, Protein J., 36, 1, 10.1007/s10930-017-9696-z · DOI · Paper page
  127. Skipper, 1996, An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins, J. Exp. Med., 183, 527, 10.1084/jem.183.2.527 · DOI · Paper page
  128. Sofron, 2016, High-resolution analysis of the murine MHC class II immunopeptidome, Eur. J. Immunol., 46, 319, 10.1002/eji.201545930 · DOI · Paper page
  129. Song, 2021, Post-translational modification control of viral DNA sensors and innate immune signaling, Adv. Virus Res., 109, 163, 10.1016/bs.aivir.2021.03.001 · DOI
  130. Speir, 1999, Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL, Immunity, 10, 51, 10.1016/s1074-7613(00)80006-0 · DOI
  131. Stern, 2016, The melting pot of the MHC II peptidome, Curr. Opin. Immunol., 40, 70, 10.1016/j.coi.2016.03.004 · DOI · Paper page
  132. Sterner, 2000, Acetylation of histones and transcription-related factors, Microbiol. Mol. Biol. Rev., 64, 435, 10.1128/mmbr.64.2.435-459.2000 · DOI · Paper page
  133. Sun, 2020, Ligand design for specific MHC class I molecules on the cell surface, Biochemistry, 59, 4646, 10.1021/acs.biochem.0c00735 · doi:10.1021/acs.biochem.0c00735
  134. Suzuki, 2016, The cytoplasmic peptide:N-glycanase (NGLY1) - structure, expression and cellular functions, Gene, 577, 1, 10.1016/j.gene.2015.11.021 · DOI · Paper page
  135. Thomas, 2021, Altered glycosylation in cancer: A promising target for biomarkers and therapeutics, Biochimica Biophysica Acta - Rev. Cancer, 1875, 188464, 10.1016/j.bbcan.2020.188464 · DOI · Paper page
  136. Ting, 2018, The interplay between citrullination and HLA-DRB1 polymorphism in shaping peptide binding hierarchies in rheumatoid arthritis, J. Biol. Chem., 293, 3236, 10.1074/jbc.ra117.001013 · DOI · Paper page
  137. Unanue, 2016, Variations in MHC class II antigen processing and presentation in health and disease, Annu. Rev. Immunol., 34, 265, 10.1146/annurev-immunol-041015-055420 · DOI · Paper page
  138. van Hall, 2012, Mechanisms of peptide vaccination in mouse models: Tolerance, immunity, and hyperreactivity, Adv. Immunol., 114, 51, 10.1016/B978-0-12-396548-6.00003-2 · DOI
  139. van Hall, 2006, Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants, Nat. Med., 12, 417, 10.1038/nm1381 · DOI · Paper page
  140. van Stipdonk, 2009, Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100, Cancer Res., 69, 7784, 10.1158/0008-5472.can-09-1724 · DOI · Paper page
  141. Velloso, 2004, Determination of structural principles underlying three different modes of lymphocytic choriomeningitis virus escape from CTL recognition, J. Immunol., 172, 5504, 10.4049/jimmunol.172.9.5504 · DOI · Paper page
  142. Vigneron, 2004, An antigenic peptide produced by peptide splicing in the proteasome, Science, 304, 587, 10.1126/science.1095522 · DOI · Paper page
  143. Vizcaíno, 2020, The human immunopeptidome project: A roadmap to predict and treat immune diseases, Mol. Cell. Proteomics, 19, 31, 10.1074/mcp.r119.001743 · DOI · Paper page
  144. Warren, 2006, An antigen produced by splicing of noncontiguous peptides in the reverse order, Science, 313, 1444, 10.1126/science.1130660 · DOI · Paper page
  145. Wolfert, 2013, Adaptive immune activation: Glycosylation does matter, Nat. Chem. Biol., 9, 776, 10.1038/nchembio.1403 · DOI · Paper page
  146. Wolpert, 1997, Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells, Proc. Natl. Acad. Sci. U. S. A., 94, 11496, 10.1073/pnas.94.21.11496 · DOI
  147. Wu, 2018, TSNAdb: A database for tumor-specific neoantigens from immunogenomics data analysis, Genomics Proteomics Bioinforma., 16, 276, 10.1016/j.gpb.2018.06.003 · DOI · Paper page
  148. Yamamoto, 2019, Identification and structure of an MHC class I–encoded protein with the potential to PresentN-myristoylated 4-mer peptides to T cells, J. I., 202, 3349, 10.4049/jimmunol.1900087 · DOI
  149. Yi, 2021, caAtlas: An immunopeptidome atlas of human cancer, iScience, 24, 103107, 10.1016/j.isci.2021.103107 · DOI · Paper page
  150. Zarling, 2006, Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy, Proc. Natl. Acad. Sci. U. S. A., 103, 14889, 10.1073/pnas.0604045103 · DOI · Paper page
  151. Zavala-Cerna, 2014, The clinical significance of posttranslational modification of autoantigens, Clin. Rev. Allergy Immunol., 47, 73, 10.1007/s12016-014-8424-0 · DOI
  152. Zhang, Metabolic regulation of gene expression by histone lactylation, Nature, 574, 575, 10.1038/s41586-019-1678-1 · DOI · Paper page
  153. Zhang, Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy, Biomed. Pharmacother., 120, 109542, 10.1016/j.biopha.2019.109542 · DOI · Paper page

Cited by

See all 21

Metadata

Authors
Sandalova, T., Sala, B. M., & Achour, A.
Venue
Frontiers in Chemistry
Published
2022-08-09
Volume
10
ISSN
2296-2646
Cited by
21
References
14

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Structural aspects of chemical modifications in the MHC-restricted immunopeptidome; Implications for immune recognition. https://app.cochat.ai/papers/10.3389/fchem.2022.861609
The paper
Sandalova, T., Sala, B. M., & Achour, A. (2022). Structural aspects of chemical modifications in the MHC-restricted immunopeptidome; Implications for immune recognition. Frontiers in Chemistry. https://doi.org/10.3389/fchem.2022.861609

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.